AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11140366 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy drink (caffeine, taurine, glucuronolactone)
Number of subjects: 10
Study 11140366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9109749 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline high dose (225 mg)
Number of subjects: 343
Study 9109749 — intervention group
Group type: EXPERIMENTAL
Intervention: Xanomeline (dose-dependent)
Number of subjects: 343
Study 9109749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343
Study 8225682 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg b.i.d. misoprostol
Number of subjects: 42
Study 8225682 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 3512420 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir alone
Number of subjects: 40
Study 3512420 — intervention group
Group type: EXPERIMENTAL
Intervention: oral acyclovir plus co‐trimoxazole
Number of subjects: 40
Study 3512420 — intervention group
Group type: COMPARATOR
Intervention: placebo alone
Number of subjects: 40
Study 3512420 — intervention group
Group type: COMPARATOR
Intervention: placebo plus co‐trimoxazole
Number of subjects: 40
Study 3512420 — intervention group
Group type: EXPERIMENTAL
Intervention: co‐trimoxazole
Number of subjects: 40
Study 31633746 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic depression screening with notification of primary care clinicians and provision of centralized, patient-preference, stepped depression care for those with positive screening results (n=499)
Number of subjects: 1500
Study 31633746 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic depression screening with notification of primary care clinicians for those with positive screening results (n=501)
Number of subjects: 1500
Study 31633746 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no screening) (n=500)
Number of subjects: 1500
Study 30646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 86017
Study 30646140 — intervention group
Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 86017
Study 30646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox-adjusted analysis for CEA
Number of subjects: 86017
Study 30646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Propensity-matched analysis for CEA
Number of subjects: 86017
Study 30646140 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable analysis for CEA
Number of subjects: 86017
Study 27282261 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI plus rebamipide (300 mg/day)
Number of subjects: 130
Study 27282261 — intervention group
Group type: COMPARATOR
Intervention: PPI monotherapy (10 mg/day)
Number of subjects: 130
Study 25035199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX) to 79.2 Gy in 66 fractions of 1.2 Gy given twice a day
Number of subjects: 250
Study 25035199 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (SFX) to 70 Gy in 35 fractions given once a day
Number of subjects: 250
Study 25035199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX)
Number of subjects: 250
Study 25035199 — intervention group
Group type: COMPARATOR
Intervention: Standard fractionation (SFX)
Number of subjects: 250
Study 25035199 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfractionation (HFX) and Standard fractionation (SFX)
Number of subjects: 250
Study 22787053 — intervention group
Group type: EXPERIMENTAL
Intervention: MABT5102A (MABT), a humanized anti-Aβ monoclonal antibody of IgG4 isotype
Number of subjects: 0
Study 22787053 — intervention group
Group type: EXPERIMENTAL
Intervention: MABT5102A (MABT)
Number of subjects: 0
Study 20019086 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-gemcitabine (DG)
Number of subjects: 0
Study 20019086 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine-cisplatin (VC)
Number of subjects: 0
Study 18936396 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐pulsed 755‐nm alexandrite laser (12‐mm spot size)
Number of subjects: 20
Study 18936396 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐pulsed 755‐nm alexandrite laser (18‐mm spot size)
Number of subjects: 20
Study 18936396 — intervention group
Group type: EXPERIMENTAL
Intervention: long‐pulsed 1064‐nm Nd:YAG laser
Number of subjects: 20
Study 18936396 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of long‐pulsed 1064‐nm Nd:YAG laser and long‐pulsed 755‐nm alexandrite laser
Number of subjects: 20
Study 18936396 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy
Number of subjects: 20
Study 15821526 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg tablets
Number of subjects: 1157
Study 15821526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1157
Study 12819976 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with verteporfin
Number of subjects: 25
Study 12819976 — intervention group
Group type: COMPARATOR
Intervention: Control group (no photodynamic therapy)
Number of subjects: 25
Study 10532139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (100 mg every 12 hours for three days)
Number of subjects: 82
Study 10532139 — intervention group
Group type: COMPARATOR
Intervention: Nitazoxanide (100 mg every 12 hours for three days)
Number of subjects: 82
Study 10532139 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 82
Study 10532139 — intervention group
Group type: COMPARATOR
Intervention: Nitazoxanide
Number of subjects: 82
Study 8752779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 30 mg before surgical incision (group A)
Number of subjects: 46
Study 8752779 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentazocine 60 mg before surgical incision (group A)
Number of subjects: 46
Study 8752779 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 30 mg after abdominal incision (group B)
Number of subjects: 46
Study 8752779 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 60 mg after abdominal incision (group B)
Number of subjects: 46
Study 1833105 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil extract (total EPA dose of 2.4 g/day) for 6 weeks
Number of subjects: 6
Study 1833105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil) for 6 weeks
Number of subjects: 6
Study 7096142 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl (300 mg/kg body wt) to induce acidosis
Number of subjects: 6
Study 7096142 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 to induce alkalosis
Number of subjects: 6
Study 7096142 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 as placebo
Number of subjects: 6
Study 31428434 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation programme
Number of subjects: 36
Study 31428434 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 36
Study 30596708 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neutrophil counts >3500 cells/mm3
Number of subjects: 801
Study 30596708 — intervention group
Group type: COMPARATOR
Intervention: Baseline neutrophil counts ≤1000 cells/mm3
Number of subjects: 801
Study 30596708 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated neutrophil count
Number of subjects: 801
Study 26957103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedar Project WelTel mHealth intervention (mobile phone, cellular plan, weekly two-way text messaging, support from Cedar Case Managers)
Number of subjects: 200
Study 26957103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cedar Project WelTel mHealth intervention
Number of subjects: 200
Study 25031230 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (skin temperature ≈34°C)
Number of subjects: 10
Study 25031230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (+1.2 ± 0.1°C increase in internal temperature, skin temperature ≈39°C)
Number of subjects: 10
Study 25031230 — intervention group
Group type: EXPERIMENTAL
Intervention: LBNP tolerance during hyperthermia
Number of subjects: 10
Study 22349946 — intervention group
Group type: COMPARATOR
Intervention: Ethanol treatment for 0s (control group) with Adper™ Scotchbond™ Multi‐Purpose (Scotchbond)
Number of subjects: 5
Study 22349946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol treatment for 20s (Group 1) with hydrophobic adhesive
Number of subjects: 5
Study 22349946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol treatment for 60s (Group 2) with hydrophobic adhesive
Number of subjects: 5
Study 22349946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol treatment for three 60s periods (Group 3) with hydrophobic adhesive
Number of subjects: 5
Study 22349946 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise ethanol application (Group 4) with hydrophobic adhesive
Number of subjects: 5
Study 20831571 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute music intervention for 4 weeks
Number of subjects: 66
Study 20831571 — intervention group
Group type: COMPARATOR
Intervention: Rest period for 4 weeks (Control)
Number of subjects: 66
Study 17714101 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapies for neuropathic pain
Number of subjects: 0
Study 16227728 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation of the soft palate
Number of subjects: 88
Study 12628946 — intervention group
Group type: COMPARATOR
Intervention: Angioplasty
Number of subjects: 588
Study 12628946 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare Stenting
Number of subjects: 588
Study 12628946 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated Stenting
Number of subjects: 588
Study 10566714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg i.v. before stenting, followed by 250 mg orally twice per day)
Number of subjects: 58
Study 10566714 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic stenting alone
Number of subjects: 58
Study 10566714 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 58
Study 10172792 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 100 mg twice daily for 5 days
Number of subjects: 575
Study 10172792 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin 1 MIU 3 times daily for 10 days
Number of subjects: 575
Study 10172792 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin-clavulanic acid 500/125 mg 3 times daily for 10 days
Number of subjects: 575
Study 2019131 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective flora suppression (polymyxin E, tobramycin, and amphotericin B)
Number of subjects: 200
Study 2019131 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective flora suppression
Number of subjects: 200
Study 2019131 — intervention group
Group type: COMPARATOR
Intervention: Control (paste and suspension without antimicrobial agents)
Number of subjects: 200
Study 2019131 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients received cefotaxime during the first 4 days
Number of subjects: 200
Study 6778548 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilisation at home with a plaster-of-Paris cylinder
Number of subjects: 0
Study 6778548 — intervention group
Group type: COMPARATOR
Intervention: Bed rest for 48 hours in hospital
Number of subjects: 0
Study 31008734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh RBC units (short-term storage)
Number of subjects: 0
Study 31008734 — intervention group
Group type: COMPARATOR
Intervention: Old RBC units (long-term storage)
Number of subjects: 0
Study 28459161 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 sessions of acupuncture
Number of subjects: 45
Study 28459161 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 sessions of acupuncture
Number of subjects: 45
Study 28459161 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 sessions of acupuncture
Number of subjects: 45
Study 28459161 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 45
Study 26387117 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force (CF)‐guided ablation with a target CF of 20 g
Number of subjects: 120
Study 26387117 — intervention group
Group type: COMPARATOR
Intervention: Blind group (operators blinded to CF information)
Number of subjects: 120
Study 23858722 — intervention group
Group type: EXPERIMENTAL
Intervention: NIP without dysplasia
Number of subjects: 55
Study 23858722 — intervention group
Group type: EXPERIMENTAL
Intervention: NIP with dysplasia
Number of subjects: 55
Study 23858722 — intervention group
Group type: EXPERIMENTAL
Intervention: NIP with malignant transformation to SCC
Number of subjects: 55
Study 23858722 — intervention group
Group type: COMPARATOR
Intervention: Control group (NM)
Number of subjects: 55
Study 22307382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression therapy (3 h daily for 3 months)
Number of subjects: 31
Study 22307382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IPC therapy)
Number of subjects: 31
Study 18815815 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine treatment
Number of subjects: 40
Study 18815815 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 40
Study 17531002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent gp120 vaccine
Number of subjects: 0
Study 17531002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17531002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk individuals
Number of subjects: 0
Study 17531002 — intervention group
Group type: COMPARATOR
Intervention: Low-risk individuals
Number of subjects: 0
Study 10811335 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran 20 g/day
Number of subjects: 60
Study 10811335 — intervention group
Group type: COMPARATOR
Intervention: Olestra 20 g/day
Number of subjects: 60
Study 10811335 — intervention group
Group type: COMPARATOR
Intervention: Olestra 40 g/day
Number of subjects: 60
Study 8650463 — intervention group
Group type: EXPERIMENTAL
Intervention: Missile warfare exposure during the Gulf War
Number of subjects: 1045
Study 8650463 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-war condition
Number of subjects: 1045
Study 1610651 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct revascularization
Number of subjects: 143
Study 1610651 — intervention group
Group type: COMPARATOR
Intervention: Crossover bypass
Number of subjects: 143
Study 6720548 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem (360 mg/day)
Number of subjects: 15
Study 30696554 — intervention group
Group type: EXPERIMENTAL
Intervention: Steareth 30 toothpaste
Number of subjects: 30
Study 30696554 — intervention group
Group type: COMPARATOR
Intervention: SLS toothpaste
Number of subjects: 30
Study 29749262 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg every night)
Number of subjects: 40
Study 29749262 — intervention group
Group type: COMPARATOR
Intervention: Oxazepam (10 mg every night)
Number of subjects: 40
Study 26912554 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (6 g in three divided doses per day)
Number of subjects: 579
Study 26912554 — intervention group
Group type: COMPARATOR
Intervention: Control (standard conventional treatment)
Number of subjects: 579
Study 23968597 — intervention group
Group type: EXPERIMENTAL
Intervention: RESMENA diet
Number of subjects: 93
Study 23968597 — intervention group
Group type: COMPARATOR
Intervention: Control (AHA guidelines)
Number of subjects: 93
Study 22995597 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch (TT)
Number of subjects: 38
Study 22995597 — intervention group
Group type: COMPARATOR
Intervention: Nursing presence
Number of subjects: 38
Study 20013165 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate (LC)
Number of subjects: 63
Study 20013165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fat Low-Carbohydrate (HFLC)
Number of subjects: 63
Study 20013165 — intervention group
Group type: COMPARATOR
Intervention: Unrestricted (UR)
Number of subjects: 63
Study 20013165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratios of MyoSUV(max) to liver SUV(max)
Number of subjects: 63
Study 17903230 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Number of subjects: 129
Study 17903230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 16143691 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine enema
Number of subjects: 24
Study 16143691 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid foam
Number of subjects: 24
Study 16143691 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ASA enema
Number of subjects: 24
Study 16143691 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid liquid enema
Number of subjects: 24
Study 16143691 — intervention group
Group type: COMPARATOR
Intervention: Overall retention
Number of subjects: 24
Study 16143691 — intervention group
Group type: COMPARATOR
Intervention: Overall preference
Number of subjects: 24
Study 12081277 — intervention group
Group type: EXPERIMENTAL
Intervention: High contextual interference condition
Number of subjects: 38
Study 12081277 — intervention group
Group type: COMPARATOR
Intervention: Low contextual interference condition
Number of subjects: 38
Study 10051494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg orally once daily for 52 weeks
Number of subjects: 125
Study 10051494 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 26 weeks
Number of subjects: 125
Study 10051494 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine treatment
Number of subjects: 125
Study 8777591 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA)
Number of subjects: 13
Study 8777591 — intervention group
Group type: COMPARATOR
Intervention: Conventional angiography and venography
Number of subjects: 13
Study 8777591 — intervention group
Group type: COMPARATOR
Intervention: Conventional arteriography and venography
Number of subjects: 13
Study 2147377 — intervention group
Group type: COMPARATOR
Intervention: Enalapril maleate 20 mg once daily, increased to 40 mg once daily in 14 patients, with 12.5 mg hydrochlorothiazide added in 5 patients.
Number of subjects: 18
Study 2147377 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 weeks) followed by enalapril maleate treatment.
Number of subjects: 18
Study 31145227 — intervention group
Group type: COMPARATOR
Intervention: Pubococcygeal (PC) sling
Number of subjects: 21
Study 31145227 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus fascia sling
Number of subjects: 21
Study 31425504 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-methyltetrahydrofolate (10.4 μg/100 ml)
Number of subjects: 120
Study 31425504 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (10.0 μg/100 ml)
Number of subjects: 120
Study 28574779 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose trastuzumab (HD) 10 mg/kg every 3 weeks
Number of subjects: 248
Study 28574779 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) trastuzumab 6 mg/kg every 3 weeks
Number of subjects: 248
Study 28574779 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose trastuzumab (HD)
Number of subjects: 248
Study 28574779 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (SoC) trastuzumab
Number of subjects: 248
Study 25651246 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary-sinus reducing device
Number of subjects: 104
Study 25651246 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 104
Study 24280470 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 100
Study 24280470 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound
Number of subjects: 100
Study 24280470 — intervention group
Group type: COMPARATOR
Intervention: Time control
Number of subjects: 100
Study 21453540 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps/day
Number of subjects: 30
Study 21453540 — intervention group
Group type: COMPARATOR
Intervention: 30 minutes of walking/day
Number of subjects: 30
Study 21453540 — intervention group
Group type: COMPARATOR
Intervention: Comparison between 10,000 steps and 30 minutes groups
Number of subjects: 30
Study 20171351 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg ibuprofen
Number of subjects: 100
Study 20171351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18157892 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 319
Study 18157892 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbing symptoms
Number of subjects: 319
Study 18157892 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance and hyperarousal
Number of subjects: 319
Study 18157892 — intervention group
Group type: EXPERIMENTAL
Intervention: Reexperiencing
Number of subjects: 319
Study 18157892 — intervention group
Group type: EXPERIMENTAL
Intervention: Numbing
Number of subjects: 319
Study 15868627 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate
Number of subjects: 137
Study 15868627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 15868627 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare status
Number of subjects: 137
Study 12468609 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of dried mango with 5 g of fat, 5 d/wk for 4 mo
Number of subjects: 176
Study 12468609 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of dried mango without fat, 5 d/wk for 4 mo
Number of subjects: 176
Study 12468609 — intervention group
Group type: EXPERIMENTAL
Intervention: 60,000 micro g of vitamin A capsule at baseline
Number of subjects: 176
Study 12468609 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule at baseline
Number of subjects: 176
Study 9618753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) treatment, cumulative 3.5 mg
Number of subjects: 19
Study 9618753 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 19
Study 9618753 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy adults
Number of subjects: 19
Study 9618753 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma cortisol concentrations
Number of subjects: 19
Study 9098473 — intervention group
Group type: EXPERIMENTAL
Intervention: Human follicular fluid (hFF) treatment (50% diluted)
Number of subjects: 0